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ABSTRACT
Oxidative stress is a feature of many common diseases. It leads to excessive formation and subsequent
release of the mitochondrial metabolite succinate, which acts as a signalling molecule through binding
the succinate receptor (SUCNR1). Recently, a potential role for SUCNR1 was proposed in age-related
macular degeneration (AMD), a common cause of vision loss in the elderly associated with increased
oxidative stress. Here, we evaluated the potential effect of genetic variants in SUCNR1 on its expression
through differential micro-RNA (miRNA) binding to target mRNA, and investigated the relevance of
altered SUCNR1 expression in AMD pathogenesis.
We analysed common SUCNR1 SNPs for potential miRNA binding sites and identified rs13079080,
located in the 3ʹ-UTR and binding site for miRNA-4470. Both miRNA-4470 and SUCNR1 were found to be
expressed in human retina. Moreover, using a luciferase reporter assay, a 60% decrease in activity was
observed when miRNA-4470 was co-expressed with the C allele compared to the T allele of rs13079080.
Finally, genotyping rs13079080 in an AMD case-control cohort revealed a protective effect of the TT
genotype on AMD compared to the CC genotype (p = 0.007, odds ratio = 0.66). However, the association
was not confirmed in the case-control study of the International AMD Genomics Consortium.
Our study demonstrates that the T allele of rs13079080 in SUCNR1 disrupts a binding site for miRNA-
4470, potentially increasing SUCNR1 expression and consequently increasing the capacity of sensing and
dealing with oxidative stress. Therefore, it would be worthwhile assessing the relevance of rs13079080 in
other oxidative stress-associated diseases in future studies.
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Oxidative stress is a shared feature of many common diseases,
such as diabetes mellitus (DM), chronic kidney disease and
cancer, and is known to coincide with alterations in the
tricarboxylic acid (TCA) cycle, leading to excessive formation
and subsequent release of the mitochondrial metabolite suc-
cinate [1]. Recently, it became apparent that released succi-
nate can act as a signalling molecule through binding to its
GPR91 plasma membrane receptor, subsequently renamed the
succinate receptor (SUCNR1). This receptor couples distur-
bances in energy metabolism to adaptive responses such as
blood pressure regulation and inducing the release of extra-
cellular factors [2,3].
The SUCNR1 gene is expressed in several tissues including
the retinal pigment epithelium (RPE) [4], the proximal and
distal tubules of the kidney [2,5] and dendritic cells [2,6].
Sucnr1 knockout mouse studies revealed that Sucnr1 activa-
tion in the kidney confers hypertension in induced DM type-1
[5,7]. Furthermore, we recently observed that Sucnr1 knock-
out mice are less diabetic compared to their wild-type litter-
mates after exposure to a high-fat diet [8]. Consequently,
SUCNR1 modulators are considered as highly promising
novel pharmaceuticals to treat these common diseases [2].
However, the role of SUCNR1 in these disorders is poorly
understood and a clear role in human (patho)physiology has
never been demonstrated. Recently, however, a potential role
for SUCNR1 was proposed in age-related macular degenera-
tion (AMD) [9].
AMD is the leading cause of vision impairment in elderly
people in the Western world, and its prevalence is expected to
rise to 200 million individuals by the year 2020 due to the
exponential aging of the population [10]. AMD is
a degenerative disease of the macula and is characterized by
extracellular deposits known as drusen. Drusen contain lipids,
lipoproteins and inflammatory factors [11,12], are found
between the RPE layer and the Bruchs’ membrane [13], and
are associated with reduced functionality of the RPE layer
[14]. Advanced AMD is classified in two forms based on
their pathological features. The first form is ‘dry’ AMD, and
is characterized by RPE and photoreceptor cell loss known as
geographic atrophy [15]. Due to extensive neovascularization
of the choroidal microvascular bed, the second form is called
‘wet’ AMD [15]. A known stimulator for choroidal neovascu-
larization is vascular endothelial growth factor (VEGF) [16].
Wet AMD patients can be treated by targeting VEGF by
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intraocular injections of anti-VEGF, which has led to
a significant improvement in visual acuity [17].
Increased oxidative stress is considered to be a key factor
underlying AMD pathogenesis. The macula is susceptible to
oxidative stress due to its high metabolic activity, high oxygen
pressure from the choroidal blood flow, and exposure to
bright light [18]. Moreover, in mice, the Sucnr1 has been
linked to AMD, as stress-induced activation of Sucnr1 has
been shown to increase Vegfa production in the retina [19].
Furthermore, Sucnr1 knockout mice developed lipid accumu-
lations between the RPE and Bruchs’ membrane, resembling
drusen seen in AMD [9]. After reintroduction of the Sucnr1
into the immune system of the knockout mice, infiltration of
macrophages into the retina and neovascularization was
observed [9]. Additionally, an association of a single nucleo-
tide polymorphism (SNP) in an intron of the SUCNR1 gene
with AMD was reported [9], further supporting a potential
role for SUCNR1 in AMD pathogenesis.
Since 25 years, it has been realized that expression of
genes can be regulated by small RNA molecules later
termed micro-RNAs (miRNA) [20] and it is suggested that
over a third of the genes in the human genome are regu-
lated by miRNAs [21]. MiRNAs regulate gene expression
post-transcriptionally [22] by binding the 3ʹ-UTR region of
mRNAs after which the mRNA is targeted for RISC-
mediated degradation or translational arrest occurs [23].
In this study we aimed to evaluate the effect of genetic
variants on regulation of SUCNR1 through miRNA binding
alteration, and to investigate the relevance of altered
SUCNR1 expression in AMD pathogenesis. We indeed iden-
tified a SNP in the 3ʹ-UTR of the SUCNR1 gene and this
transcript predicted to disrupt a binding site for miRNA-
4470, which was predicted to be expressed in the retina by
previous studies [24]. The expression of the miRNA and
SUCNR1 in the retina were assessed and the effect of
miRNA-4470 on SUCNR1 mRNA expression was further
investigated. Additionally, the association of the SNP with
AMD was analysed in an AMD case-control cohort.
Results
SNPs in the SUCNR1 gene affecting miRNA binding sites
To determine whether SUCNR1 expression could be influenced
by genetic variants leading to altered miRNA binding, we
analysed all SNPs (minor allele frequency (MAF) >0.01) in
the SUCNR1 gene for potential miRNA binding sites. In silico
analysis of the SUCNR1 gene revealed 48 common SNPs, of
which 35 SNPs (73%) were found in intronic regions and 12
SNPs (25%) were found in the 3ʹ-UTR (Table 1). Only one SNP
was found in the coding region but was located at the 5ʹ-end of
exon 3, a location that has never been reported to be regulated
by miRNAs. Analysis of the SNPs found in the 3ʹ-UTR with the
online available mirSNP tool [25] revealed four SNPs that are
predicted to affect binding of miRNAs (Table 2). In total, 12
miRNAs were found of which the binding was predicted to be
affected by these four SNPs. The effect of the minor allele
compared to the major allele of each SNP ranged from creating
a miRNA binding site (create), disrupting a miRNA binding
site (break), to creating a stronger or less strong miRNA bind-
ing (enhance and decrease, respectively).
Expression of miRNA-4470 and SUCNR1 in the retina
To assess the potential relevance of the four miRNA binding sites
in AMD pathogenesis, the expression of the miRNAs and
SUCNR1 in the human retina and RPE was determined.
Evaluation of online-available RNA-seq databases revealed that,
in line with literature [4], SUCNR1 is expressed in human
retina and significantly more in RPE-choroid-sclera tissue
(p = 6.63x10−5, Figure 1A). Of the potential SUCNR1-regulating
miRNAs, only miRNA-4470 was found to be significantly higher
expressed in RPE cells derived fromhuman embryonic or induced
pluripotent stem cells (p = 0.03, Figure 1B and figure S1, respec-
tively) compared to non-differentiated stem cells. Because
miRNA-4470 was only reported to be expressed in in vitro derived
RPE cells, a condition known to often change RNA expression
levels as compared to in vivo, we tested two primary human
retina-RPE-choroid samples for miRNA-4470 expression.
Monocyte derived dendritic cells (moDCs) were used as
a positive control because these cells have been shown to express
miRNA-4470 [26]. Indeed, the expected 59-basepair product was
amplified from RNA derived from primary retina-RPE-choroid
samples as well as the moDC positive control, but not from their
reverse transcriptase (-RT) negative control (Figure 1C).
Subsequent sequence analysis of these fragments confirmed that
the product corresponded to miRNA-4470 (not shown). These
data revealed that the SUCNR1 gene and miRNA-4470 are both
expressed in the human retina.
Regulation of SUCNR1 expression by miRNA-4470
depending on the rs13079080 allele
In silico evaluation of SNP rs13079080 revealed that the major
C allele is predicted to form a miRNA-4470 binding site in the
3ʹ-UTR of the SUCNR1 gene transcript (Figure 2A). When the
minor T allele is present in the 3ʹ-UTR of the SUCNR1 gene
transcript, the micro-RNA binding site is predicted to be
disrupted (Figure 2A). To assess whether miRNA-4470 indeed
decreases the mRNA levels of the SUCNR1 gene transcript
carrying the major C allele, but not in the presence of the
minor T allele of rs13079080, a luciferase assay was carried
out. The 3ʹ-UTRs were cloned in luciferase assay reporter
constructs and tested for binding and degradation by
miRNA-4470 or a scrambled negative control miRNA follow-
ing transfection in HEK293 cells. Indeed, miRNA-4470 co-
transfection resulted in a significant decrease in luciferase
activity derived from the C allele construct as compared
to the scrambled miRNA co-transfection condition
(p = 2.25x10−5), whereas no effect was observed when
miRNA-4470 was co-transfected with the T allele construct
or the empty vector (Figure 2B). A 60% reduction in luciferase
activity was observed when comparing both alleles co-
transfected with miRNA-4470. Co-transfection with the
scrambled miRNA did not affect luciferase activity derived
from of either construct. These data indicate that the expres-
sion of the SUCNR1 with the C, but not the T, allele is indeed
affected by miRNA-4470.
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Association analysis of rs13079080 with AMD
To assess whether the SNP (rs13079080) in the miRNA-4470
binding site is associated with AMD development, we genotyped
this SNP in a cohort of 1,784 individuals, of which 848 were
graded as AMD (including all stages) and 936 as controls.
Demographics of the EUGENDA case-control cohort is
described in Table 3. In this case-control cohort, the SNP
rs13079080 was associated with AMD (p = 0.008, adjusted for
age and sex). The association was driven by the homozygous
alternative genotype TT, which was associated with a reduced
risk for AMD when compared to the homozygous reference CC
genotype (p = 0.007, OR = 0.66, 95% CI = 0.49–0.89). The
heterozygous genotype CT was not associated with AMD
(p = 0.780, OR = 1.03, 95% CI = 0.83–1.26).
We additionally explored whether this association was
identified in the largest GWAS on advanced AMD published
to date [27]. This study included 16,144 advanced AMD
patients and 17,832 controls from 25 different cohorts and
analysed >12 million genetic variants. Here, SNP rs13079080
was not associated with advanced AMD in the pooled analysis
(p = 0.54, OR = 1.01, 95% CI = 0.98–1.04). A more detailed
analysis of this SNP in 22 of the assessed cohorts showed
a nominal association (p < 0.05) for the Edinburgh cohort
and no association for the remaining cohorts. However, the
direction of the effect in the Edinburgh cohort was the oppo-
site compared to the effect observed in the EUGENDA case-
control cohort (p = 0.03, OR = 1.36, 95%CI = 1.03–1.79, Table
S1). These data indicate that rs13079080 was associated with
AMD in the EUGENDA cohort, but this association was not
confirmed in the IAMDGC dataset.
Discussion
In this study, we identified a SNP (rs13079080) in the 3ʹ-UTR
of the SUCNR1 gene transcript that affects a binding site for
miRNA-4470. We demonstrate that the SUCNR1 gene and
miRNA-4470 are both expressed in the human retina/RPE,
and describe that miRNA-4470 binds to the major C allele of
Table 1. SNPs in SUCNR1 gene.
SNP Change in allele Allele frequency Location in the gene Chromosome location
rs1445359 A/G 0.960863/0.039137 intron 151873953
rs76861810 C/T 0.981230/0.018770 intron 151874048
rs13090483 C/T 0.023363/0.976637 intron 151874117
rs9855643 A/G 0.489816/0.510184 intron 151874810
rs76992305 A/G 0.968850/0.031150 intron 151875177
rs78598704 C/T 0.955072/0.044928 intron 151875205
rs1445358 A/G 0.151158/0.848842 intron 151875430
rs79020368 C/G 0.044928/0.955072 intron 151875605
rs77221620 G/T 0.968850/0.031150 intron 151875836
rs78279353 A/T 0.014377/0.985623 intron 151875973
rs9828478 G/T 0.739417/0.260583 intron 151876506
rs1520211 C/G 0.868610/0.131390 intron 151876532
rs1520212 A/T 0.868610/0.131390 intron 151876533
rs1520213 G/T 0.131589/0.868411 intron 151876768
rs112099950 C/T 0.027756/0.972244 intron 151876775
rs1520214 A/G 0.868411/0.131589 intron 151876831
rs9824780 C/T 0.261781/0.738219 intron 151877081
rs1476177 A/T 0.486022/0.513978 intron 151877667
rs80251978 C/T 0.043331/0.956669 intron 151877817
rs78717519 C/T 0.010982/0.989018 intron 151878205
rs75824320 A/G 0.031150/0.968850 intron 151878550
rs62272956 A/C 0.989018/0.010982 intron 151878552
rs7638353 A/C 0.512181/0.487819 intron 151878612
rs12632021 G/T 0.132388/0.867612 intron 151878616
rs9811297 A/C 0.098043/0.901957 intron 151878800
rs79257023 C/T 0.031150/0.968850 intron 151878919
rs2030370 C/T 0.525160/0.474840 intron 151878997
rs12486484 C/T 0.486621/0.513379 intron 151879385
rs1850963 A/T 0.486821/0.513179 intron 151879460
rs13315275 A/G 0.340256/0.659744 intron 151879522
rs58487215 C/T 0.050719/0.949281 intron 151879695
rs73168928 C/T 0.116014/0.883986 intron 151880081
rs75265510 A/G 0.946086/0.053914 intron 151880183
rs34882247 C/T 0.981430/0.018570 intron 151880354
rs16863710 C/T 0.971518/0.028474 coding-synon 151880681
rs200415012 A/C 0.014376/0.985624 intron/nonsense 151880687
rs13079080 C/T 0.584065/0.415935 intron/untranslated-3 151881605
rs56171835 C/T 0.859225/0.140775 intron/untranslated-3 151881694
rs73168929 A/C 0.065096/0.934904 intron/untranslated-3 151881896
rs73018440 G/T 0.071486/0.928514 intron/untranslated-3 151881934
rs73168930 C/T 0.140575/0.859425 intron/untranslated-3 151882256
rs62274881 A/C 0.013379/0.986621 intron/untranslated-3 151882419
rs71306564 A/C 0.904952/0.095048 intron/untranslated-3 151882614
rs60324356 C/T 0.928714/0.071286 intron/untranslated-3 151882995
rs6763399 C/T 0.014177/0.985823 intron/untranslated-3 151883648
rs34505768 A/T 0.973043/0.026957 intron/untranslated-3 151883894
rs73168931 A/C 0.974042/0.025959 intron/untranslated-3 151884002
rs75790719 A/C 0.946885/0.053115 intron/untranslated-3 151884195
SNPs in SUCNR1 extracted from UCSC human genome browser using the Human Dec. 2013 (GRCh38/hg38) assembly and the dbSNP151 track.
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rs13079080 leading to reduced mRNA expression, while bind-
ing of the miRNA is disrupted by the minor T allele.
Moreover, we found a protective association of the TT geno-
type of rs13079080 with AMD in the EUGENDA cohort, but
this association was not confirmed in the IAMDGC dataset.
Interestingly, rs13079080 is located in the 3ʹ-UTR of
SUCNR1 in a region corresponding with the miRNA seed
region (Figure 2A), the 5ʹ-end of the miRNA which is crucial
for target recognition [22]. More specifically, rs13079080 is
the first 5ʹ-nucleotide of the miRNA seed region. The other
SNPs found in miRNA-binding sites in the 3ʹ-UTR of
SUCNR1 were either not found in the 5ʹ-end of the miRNA,
or the corresponding miRNA was not expressed in RPE cells
in vitro (figure S1). However, that does not mean that the
other miRNA’s cannot influence the expression of SUCNR1.
The remaining SNPs could be of interest in other tissues
where both the corresponding miRNA and SUCNR1 are
expressed. Additional studies are needed to determine the
role and consequences of miRNA-4470 on SUCNR1 regula-
tion. Unfortunately, confirmation of the mRNA degradation
effect of miR-4470 on SUCNR1 gene transcript levels in
patient derived EBV cell lines did not work out due to low
transcript levels. Furthermore, miRNA-4470 is not expressed
in murine tissue [28] limiting the options for studying
SUCNR1 regulation by miRNA-4470. As an alternative, iPSC-
derived RPE or retinal organoids could be used as a model
system to study the effect of the SNP, either using cell lines
generated from carriers and non-carriers, or using isogenic
lines by introducing the variant by genome editing.
The Sucnr1 gene is expressed in murine RPE cells [4,9]
and recently a link between reduced Sucnr1 expression and
dry AMD was proposed [9]. In that study, Sucnr1 knockout
mice showed signs of sub-retinal accumulations of oxidized-
LDL, a component found in drusen. The Sucnr1 knockout
mice also show decreased expression of CD36. CD36 is
a scavenger receptor found in RPE cells where it is respon-
sible for the uptake/transport of lipids and oxidized LDL
[29]. Downregulation of CD36 (linked to and possibly
caused by downregulation of the Sucnr1) leads to ineffective
removal of these lipids and oxLDL. Eventually, this could
lead to drusen formation between RPE cells and Bruch
membrane [29] explaining the dry AMD phenotype
observed in the mice.
A role for miRNA-4470 mediated SUCNR1 mRNA reduc-
tion in AMD development is supported by expression of
miRNA-4470 and SUCNR1 in human retina tissue. SUCNR1
Table 2. SNPs in the 3ʹ-UTR of the SUCNR1 gene predicted to affect miRNA-
binding sites.




















Impact of the change is indicated as break (no miRNA binding after change),
create (no miRNA binding before change), enhance (stronger miRNA binding
after change) and decrease (less miRNA binding after change).
Figure 1. SUCNR1 and miRNA-4470 are expressed in human eye tissue. A) SUCNR1 expression (mean + SEM; n = 16) in human retina and RPE-choroid based on RNA-
seq data from Kim et al., 2018 [30]. ***, P < 0.001 by student T-test. B) MiRNA-4470 expression (mean + SEM; n = 3) at four different time points of differentiation
from hESC towards RPE cells based on RNA-seq data from Hu et al., 2012 [24]. *, P < 0.05 by one-way anova. C) Two primary human retina (hRetina) samples were
subjected to an RT-nested PCR reaction to amplify miRNA-4470. Amplified miRNA-4470 (59 bp) was visualized on agarose gel. M = marker showing bands of 50, 100
and 200 bp. – RT is the reverse transcriptase control and bl is the blanco control for the PCR reaction. RPKM, reads per kilobase mapped; ESC, embryonic stem cells;
PD, partially differentiated ESC; PC, pigmented clusters; moDCs = monocyte derived dendritic cells.
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is known to be expressed in human RPE-choroid tissue [30]
(Figure 1A) but miRNA-4470 has so far only been reported to
be expressed in human immune [26] and microglia cells [31].
In this study we demonstrate that miRNA-4470 is also
expressed in primary human eye material (Figure 1C).
In this study we identified an association of the rs13079080
SNP in the EUGENDA AMD case-control cohort, in which
the TT genotype is associated with a decreased risk for AMD
when compared to the CC genotype. No association with
AMD was observed for the heterozygous CT genotype
(Table 3). Our luciferase assay showed a significant reduction
in luciferase activity for the major C allele of rs13079080
compared to the minor T allele (Figure 2B), suggesting that
a downregulation of SUCNR1 expression could be associated
with AMD. A downregulation of SUCNR1 expression in
AMD would be in agreement with the observed AMD-like
features in Sucnr1 knockout mice [9].
However, the association between rs13079080 and
(advanced) AMD was not confirmed in the IAMDGC dataset
(table S1) [27]. The association of rs13079080 in the
EUGENDA cohort might represent a false positive finding,
or could be related to other factors not accounted for in the
analyses. The association analysis in the EUGENDA cohort
was performed on the genotype level and only the homozy-
gous group showed an association (Table 3), which suggests
a recessive effect. The AMD GWAS assumed an additive
model, which may have failed to detect the effect of the
homozygous alternative genotype [27]. Furthermore, the
EUGENDA cohort included AMD patients of all stages
whereas the AMD GWAS only included advanced AMD
patients. Repeating the analysis for the EUGENDA cohort
using only advanced AMD resulted in no significant effect
but this could be due to the limited number of patients and
controls (p = 0.358, table S2). Finally, another possibility for
the difference between the two studies is that the effect
observed in the EUGENDA cohort may be cohort-, stage of
AMD- or population-specific.
Our study demonstrates that the major C allele of
rs13079080 in the 3ʹ-UTR of SUCNR1 transcript forms
a binding site for miRNA-4470, potentially resulting in
decreased SUCNR1 expression and consequently reduced
capacity of sensing and dealing with oxidative stress. In indi-
viduals carrying the T allele, this binding site is disrupted and
therefore it is plausible that those individuals have, on the
contrary, an increased capacity of sensing and dealing with
stress. It would be worthwhile to assess the relevance of this
variant in other oxidative stress-associated disorders of which
also a possible role for SUCNR1 has been discussed, such as
hypertension, obesity-induced adipose tissue inflammation
and DM type-1 [5,7,8]. Further studies are needed to assess
the expression of miRNA-4470 in additional tissues to deter-
mine the relevance of miRNA-4470 regulated SUCNR1
expression in other stress-related disorders.
Furthermore, SUCNR1 is a highly interesting drug target
for the pharmaceutical industry, as the majority of targeted
drugs exert their action via G protein-coupled receptors like
Table 3. EUGENDA cohort and association of rs13079080 with AMD.









Female sex – n (%) 569 (60.8) 481 (56.7) 0.251 1.19 0.97–1.45
SNP rs13079080 0.008
CC – n (%) 353 (37.7) 305 (36.0) Reference
CT – n (%) 456 (48.7) 379 (44.7) 0.780 1.03 0.83–1.26
TT – n (%) 127 (13.6) 164 (19.3) 0.007 0.66 0.49–0.89
SD = standard deviation, n = number, OR = odds ratio, CI = confidence interval.
Association of rs13079080 with all stages AMD was assessed using a logistic
regression model adjusted for age and sex.
Figure 2. The minor allele of rs13079080 (T) disrupts a miRNA-binding site for and is regulated in vitro by miRNA-4470. A) In silico analysis of SNPs found in 3ʹ-UTR of
SUCNR1 using mirSNP database [25] indicated an efficient binding of miRNA-4470 with the major C allele, but not the minor T allele, of rs13079080, indicated with an
arrow. Score: The predicted score of miRNA-mRNA binding by miRanda software [33]. B) Luciferase reporter constructs carrying the SUCNR1 3ʹ-UTR segment of the
major (C) or minor (T) allele of rs13079080 (indicated) or without additional segment (empty vector) were transiently-transfected into HEK293 cells together with
a miRNA mimic 4470 (white bars) or scrambled miRNA (negative control, black bars). Only in cells transfected with the SUCNR1 C construct in conjunction with
miRNA-4470 a significant decrease in luciferase activity was detected. Data represents mean + SEM (n = 3). ***, P < 0.001 by 2-way anova.
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the SUCNR1 [2]. For other diseases in which SUCNR1 may
be involved (hypertension, obesity-induced adipose tissue
inflammation and DM type-1 [5,7,8]) stratification based on
the rs13079080 may improve the effects of such drugs.
Methods
Analysis of common variation in the SUCNR1 gene and
miRNA expression analysis
The SNPs with minor allele frequency above 0.01 found in the
SUCNR1 gene were extracted from the UCSC human genome
browser (https://genome.ucsc.edu/) using the dbSNP151 track
(Common SNPS (151), HG38, chr3:151873643–151884619).
The 12 SNPs found in the 3ʹ-UTR (untranslated-3) were ana-
lysed for miRNA binding sites using the mirSNP database [25].
Evaluation of SUCNR1 and miRNA expression in RPE was
assessed by retrieving RNA-sequencing data from the GEO
database (http://www.ncbi.nlm.nih.gov/geo/) from Kim et al
(GSE99248) [30] and Hu et al (GSE37686) [24], respectively.
Statistical analyses were performed using Graphpad Prism 5
software. One-tailed Student’s t-test or one-way ANOVA with
repeated measures, followed by Bonferroni post hoc test, was
used, as indicated in figure legends. P values < 0.05 were con-
sidered significant.
Analysis of miRNA-4470 expression
Human retina-RPE-choroid samples were obtained from
eyes removed during surgery at the Department of
Ophthalmology, Radboudumc, Nijmegen, and stored anon-
ymized at −80°C. Total RNA was isolated using TRizol
according to the manufacturers’ protocol (Invitrogen,
Breda, The Netherlands). E.coli poly(A) polymerase (New
England Biolabs, Leiden, The Netherlands) was used to add
a poly-A tail to all RNA. In short, 1 μl 10X polyadenylation
buffer, 1 μl ATP and 1 μl polymerase was added to 2 µg RNA
in 10 μl end volume and incubated at 37°C for 60 min.
Following inactivation of the polymerase (10 min at 65°C),
2.5 μl of 100 μM oligo-dT adaptor (5ʹ-
GCGAGCACAGAATTAATACGACTCACTATAGGTTTT-
TTTTTTTTAA-3ʹ) was added and incubated at 65°C for
5 min to allow for adaptor binding. After a 2 min incubation
on ice, cDNA synthesis was conducted using M-MLV
reverse transcriptase according to the manufacturer’s proto-
col and following adjustment to the used volume
(Invitrogen, Breda, The Netherlands). For the RT- negative
control a sample without RNA was taken along. MiRNA-
4470 was subsequently amplified using AmpliTAQ gold
master mix (Invitrogen, Breda, The Netherlands) using pri-
mer set 1 (forward 5ʹ- TCTGGTTGGCAAACGTGGAAG-3ʹ;
reverse 5ʹ- GCGAGCACAGAATTAATACGAC-3ʹ) and pri-
mer set 2 (forward 5ʹ- ACGTGGAAGCCGAGAAA-3ʹ;
reverse 5ʹ- GCGAGCACAGAATTAATACGAC-3ʹ) in the
first and nested PCR reaction, respectively. Nested PCR
products were visualized on agarose gels containing ethi-
dium bromide. For sequence verification of the fragments,
the DNA fragments were isolated from the agarose (Gel
Extraction/PCR Clean-up kit, Thermofisher, Amsterdam,
The Netherlands) according to the manufacturer’s protocol
and subjected to standard Sanger sequence analysis.
Cloning the 3ʹ-UTR sequences of the SUCNR1 in luciferase
constructs
Human kidney RNA was used for reverse transcription
using M-MLV reverse transcriptase in combination with random
hexamer primers according to the manufacturer’s protocol
(Invitrogen, Breda, The Netherlands). The 3ʹ-UTR of the human
SUCNR1 (1049 bp-1534 bp from the transcription start site
NM_033050.5) was amplified using a high fidelity DNA polymer-
ase (Phusion, Thermofisher, Amsterdam, The Netherlands) using
forward (5ʹ- ATAGCTCGAGATCCCTTACATCCTTTAG
CAGAT-3ʹ) and reverse (5ʹ- ATGCGGCCGCTTGCT
TAACAGCACAACTTCCAA-3ʹ) primers, flanked by XhoI and
NotI restriction sites, respectively (underlined). The PCR product
was digested with XhoI and NotI (New England Biolabs, Leiden,
The Netherlands) and ligated into the pmirGLO Dual-Luciferase
miRNA Target Expression Vector (Promega, Fitchburg, MA)
digested with the same enzymes downstream of the luciferase
gene. Ligation was performed using T4 DNA ligase (New
England Biolabs Ltd, Leiden, The Netherlands). Sanger sequen-
cing revealed that the cloned 3ʹ-UTR DNA fragment contained
the major C allele of rs13079080. The minor T allele was subse-
quently introduced by site-directed mutagenesis (Stratagene, La
Jolla, USA) on the obtained pmirGLO-SUCNR1-C construct,
using the following primer sequence: forward 5ʹ-
CTGTAAGCCAGTTACAGTTTGCTTTAACTCATAGACAT-
CAATCAG-3ʹ and reverse 5ʹ- CTGATTGATGTCTATGAGTT
AAAGCAAACTGTAACTGGCTTACAG-3ʹ. The introduction
of the T allele (pmirGLO-SUCNR1-T) was confirmed using
Sanger sequencing.
Cell culture and luciferase assay
HEK293 cells were grown in Dulbecco’s modified Eagle’s
medium (Lonza, Leusden, The Netherlands) supplemented
with 10% (v/v) fetal calf serum (FCS) and 2 mM
L-glutamine. Cells were grown at 37°C in a humidity-
controlled incubator with 5% (v/v) CO2. Cells were reseeded
in a 24-wells plate before transient transfection. Cells were
transfected using 50 ng vector DNA (pmirGLO-empty,
pmirGLO-SUCNR1-C or pmirGLO-SUCNR1-T) and 50
pmol miR-4470 mimic (UGGCAAACGUGGAAGCCGAGA)
or negative control (UCACAACCUCCUAGAAAGAG
UAGA) (Dharmacon, Lafayette, USA)) miRNA in combina-
tion with 1 μl lipofectamine 2000 (Invitrogen, Breda, The
Netherlands). DNA, vector and miRNA mimics, and lipofec-
tamine were each added to 25 µl Optimem (Thermofisher,
Amsterdam, The Netherlands) and incubated for 5 min at
room temperature. The lipofectamine/DNA mixture was
combined and incubated for 20 min at room temperature
before adding to the wells. Two days after transfection, luci-
ferase activity was measured. Renilla luciferase present in the
vector was used as an internal control for transfection effi-
ciency. Both firefly and Renilla luciferase activities were mea-
sured with the Dual-Luciferase Reporter Assay (Promega,
Fitchburg, MA) according to manufacturer’s protocol. To
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correct for differences in transfection efficiencies, the shown
firefly luciferase activity was normalization for Renilla lucifer-
ase activity. Statistical analyses were performed using
Graphpad Prism 5 software. Two-way ANOVA with repeated
measures, followed by Bonferroni post hoc test, was used, as
indicated in figure legends. P values < 0.05 were considered
significant.
Association analysis of rs13079080 and AMD
Patients and controls from the European Genetic Database
(EUGENDA) aged 65 years or older were selected for this
study. The grading of AMD was performed using multimodal
image grading according to the standard protocol of the
Cologne Image Reading Centre (CIRCL) and by certified
graders [32]. Genotyping of the rs13079080 SNP was per-
formed using competitive allele-specific KASP genotyping
chemistry (LGC, Hoddesdon, UK). Primers and probes were
developed by LGC (Primer Allele-FAM: ATCTGTAAGCCAG
TTACAGTTTGCC, Primer Allele-HEX: AATCTGTAAGCC
AGTTACAGTTTGCT, Primer Common GACACTCT
CTGATTGATGTCTATGAGTTA). Statistical analysis was
performed using IBM SPSS Statistics for Windows, version
25 (IBM Corp., Armonk, New York, USA). To determine the
association of the demographic variables and the rs13079080
SNP with AMD, a logistic regression was performed including
age and sex. The study was performed in accordance with the
tenets of the Declaration of Helsinki and the Medical
Research Involving Human Subjects Act (WMO), and was
approved by the local ethics committees. Written informed
consent was obtained from all participants. Results from the
GWAS on advanced AMD were provided by the International
AMD Genomics Consortium (IAMDGC) [27].
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